antarelix
- Product Name
- antarelix
- CAS No.
- 151272-78-5
- Chemical Name
- antarelix
- Synonyms
- antarelix;D-Alaninamide, N-acetyl-3-(2-naphthalenyl)-D-alanyl-4-chloro-D-phenylalanyl-3-(3-pyridinyl)-D-alanyl-L-seryl-L-tyrosyl-N6-(aminocarbonyl)-D-lysyl-L-leucyl-N6-(1-methylethyl)-L-lysyl-L-prolyl-
- CBNumber
- CB31383659
- Molecular Formula
- C74H100ClN15O14
- Formula Weight
- 1459.13
- MOL File
- 151272-78-5.mol
antarelix Property
- Water Solubility
- >10g/L(temperature not stated)
N-Bromosuccinimide Price
- Product number
- PEP0003615
- Product name
- ANTARELIX
- Purity
- 95.00%
- Packaging
- 1MG
- Price
- $836.8
- Updated
- 2021/12/16
- Product number
- PEP0003615
- Product name
- ANTARELIX
- Purity
- 95.00%
- Packaging
- 5MG
- Price
- $1791.41
- Updated
- 2021/12/16
antarelix Chemical Properties,Usage,Production
Uses
Teverelix (EP 24332) is a GnRH antagonist. Teverelix binds competitively and reversibly to GnRH receptors, thereby suppressing the release of LH and FSH. Teverelix can be used in the research of prostatic hyperplasia, endometriosis, and prostate cancer[1][2].
in vivo
Teverelix (3-300 μg/kg, intramuscular injection) inhibits testosterone in rats[3].
Teverelix (1 mg/kg, s.c, daily for 3 days) abolishes luteal function in stumptailed macaques[4].
| Animal Model: | Rats[3] |
| Dosage: | 300, 100, 30, 10 and 3 μg/kg |
| Administration: | Intramuscular injection |
| Result: | Showed dose-response and time-course of testosterone inhibitory activity. |
References
[1] MacLean CM, et al. Pharmacokinetic, Safety, and Pharmacodynamic Properties of Teverelix Trifluoroacetate, a Novel Gonadotropin-Releasing Hormone Antagonist, in Healthy Adult Subjects. Clin Pharmacol Drug Dev. 2022 Feb;11(2):257-269. DOI:10.1002/cpdd.1008
[2] Sperduti S, et al. GnRH Antagonists Produce Differential Modulation of the Signaling Pathways Mediated by GnRH Receptors. Int J Mol Sci. 2019 Nov 7;20(22):5548. DOI:10.3390/ijms20225548
[3] Deghenghi R, et al. Antarelix (EP 24332) a novel water soluble LHRH antagonist. Biomed Pharmacother. 1993;47(2-3):107-10. DOI:10.1016/0753-3322(93)90299-z
[4] Fraser HM, et al. Initiation of high dose gonadotrophin-releasing hormone antagonist treatment during the late follicular phase in the macaque abolishes luteal function irrespective of effects upon the luteinizing hormone surge. Hum Reprod. 1997 Mar;12(3):430-5. DOI:10.1093/humrep/12.3.430
antarelix Preparation Products And Raw materials
Raw materials
Preparation Products
antarelix Suppliers
- Tel
- 0571-87213919
- Eric@peptidego.com
- Country
- China
- ProdList
- 7408
- Advantage
- 58
- Tel
- 0571-87213919 17306812703
- 3007955328@qq.com
- Country
- China
- ProdList
- 6979
- Advantage
- 58
- Tel
- 15002134094
- marketing@targetmol.cn
- Country
- China
- ProdList
- 29257
- Advantage
- 58
- Tel
- 13758194781 15083780366
- wudegui@tanzhenbio.com
- Country
- China
- ProdList
- 1591
- Advantage
- 58
- Tel
- 18178976185
- 3855357086@qq.com
- Country
- China
- ProdList
- 2061
- Advantage
- 58
- Tel
- +1-781-999-5354;
- support@targetmol.com
- Country
- United States
- ProdList
- 39035
- Advantage
- 58
- Tel
- 18818417021
- Country
- CHINA
- ProdList
- 127
- Advantage
- 58